ABSTRACT Doxorubicin (DOX) is a widely used treatment for human cancers, but increases the risk of life-threatening congestive heart failure (CHF). DOX-induced mitochondrial damage is cumulative and persistent, similar to that observed clinically for risk of CHF. Recent evidence suggests the persistent nature of this injury is caused by altered regulation of genes important to normal cardiac functioning. We hypothesize that chronic DOX therapy is associated with epigenetic modifications of DNA methylation status, particularly in critical regulators of mitochondrial function and capacity. Cardiac tissue from Sprague Dawley rats receiving injections of DOX (2 mg/kg, s.c.) or saline once a week for 6 weeks, followed by 5 weeks of drug-free holiday was used for Reduced Representation Bisulfite Sequencing to map specific sites of DNA methylation. Comparison of these methylomes indicated DOX exposure alters DNA methylation landscapes, and identified 14 genes with highly altered methylation status. Preliminary functional effects of DNA methylation changes were characterized by quantifying mRNA expression of selected targets (Rbm20, Nmnat2, Klhl29, Cacna1c, Scn5a.) Gene expression of Rbm20, Klhl29, and Nmnat2 were significantly altered in DOX treated animals; Klhl29 and Nmnat2 demonstrated significant decreases in protein expression corresponding to gene expression. Through an epigenotype-to-phenotype approach, this study identifies potential markers and molecular regulators of irreversible DOX-induced cardiovascular toxicity associated with clinically limiting CHF. However, none of the most prevalent genes identified directly relate to mitochondrial structure or function. Thus, the investigation fails to demonstrate a direct association between this altered methylome and persistent mitochondrionopathy associated with chronic doxorubicin cardiac toxicity.
1966), and dramatically limits clinical utility. This effect, which may occur during the latter phases of drug therapy or even years later, often leads to cardiomopathy (CM) and lifethreatening congestive heart failure (CHF) (Lipshultz et al., 1991; Mettler et al., 1977; Sorensen et al., 1997; Von Hoff et al., 1979) . This latent myocardial toxicity poses an especially challenging dilemma when treating pediatric cancers because of the high risk for CHF later in life.
Because the clinical efficacy of DOX is quite high, medical and research communities have focused on investigating cardiotoxic mechanisms of DOX with hopes they may reveal opportunities to limit the incidence of CM and CHF, improving overall clinical success of the drug. Although elucidating mechanisms of DOX-induced cardiotoxicity is important to improving utility of this significant drug, so too is understanding the mechanism responsible for persistence of this toxic effect. The cumulative and persistent cardiac mitochondrial dysfunction induced by DOX has been well documented in vivo (Berthiaume and Wallace, 2007a,b; Wallace, 2003 Wallace, , 2007 Zhou et al., 2001a,b) , yet there have been few substantial efforts to further characterize this long-lasting mitochondrial dysfunction associated with drug toxicity. This "memory", or persistence of mitochondrial toxicity, is especially critical in pediatric patients, where DOXinduced CM and CHF have been observed to develop as late as 20 years posttherapy (Lipshultz et al., 1991) . This places pediatric patients at higher risk for developing severe cardiotoxic side effects with subsequent drug treatment. A possible explanation for this phenomenon, and one that is the focus of this investigation, is the role of epigenetic modulation of key regulators of mitochondrial bioenergetics.
Previous work in this laboratory has identified and described the "mitochondrial memory" or irreversible nature of DOXinduced mitochondrial toxicity in male Sprague Dawley rats (Berthiaume and Wallace, 2007a,b; Palmeira et al., 1997; Serrano et al., 1999; Wallace, 2003 Wallace, , 2007 Zhou et al., 2001a,b) . Weekly injections of DOX (2 mg/kg, i.p.) caused cumulative, dosedependent increases in concentrations of 8-hydroxydeoxyguanosine (8OHdG) adducts in both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) from both heart and liver (Palmeira et al., 1997; Serrano et al., 1999) . Interestingly, the concentration of 8OHdG adducts was 50% higher in cardiac mtDNA than liver mtDNA and twice that of cardiac nDNA, and remained elevated for 5 weeks following the last DOX injection (Serrano et al., 1999) . Associated with this was an increased rate of reactive oxygen species formation in cardiac myocytes and strong inhibition of mitochondrial calcium loading capacity, all of which are indicators of a fixed, long-lasting compromise of mitochondrial function (Wallace, 2007; Zhou et al., 2001a,b) .
These observations were corroborated by dose-dependent, irreversible histopathological changes and systematic alterations in global gene expression profiles in hearts of rats subjected to 6 weekly injections of DOX followed by a 5-week drug-free period (Berthiaume and Wallace, 2007b; Carvalho et al., 2010; Zhou et al., 2001b) . Several gene products involved in mitochondrial metabolism were suppressed. Of particular interest was decreased expression of many genes involved in aerobic fatty acid oxidation, whereas genes involved in glycolysis were increased, suggesting a switch in metabolic flux in response to the loss of mitochondrial function (Carvalho et al., 2010) .
Recent evidence demonstrates that maintenance of mitochondrial integrity is achieved through the dynamic nature of the mitochondrial population in the cell. Mixing of mitochondrial content is accomplished through fusion and fission, while grossly damaged mitochondria are selectively removed through mitophagy (Detmer and Chan, 2007; Narendra et al., 2008; Twig et al., 2008) . The significance of these long-term alterations in cardiac mitochondrial metabolism is that 5 weeks without DOX treatment represents 25 drug half-lives. It has been suggested that cardiac mitochondria turn over every 2-4 days (Kai et al., 2006; Lipsky and Pedersen, 1981) ; thus, 5 weeks without DOX treatment represents more than 8 generations of mitochondria. One would expect that any direct and reversible lesion would have resolved over the course of drug elimination and/or replacement of the population of damaged mitochondria.
The persistence of this mitochondrionopathy (Wallace, 2003) suggests DOX induces an alteration to the nuclear genome (which is sustainable through the lack of mitotic division in cardiac cells), or a heritable lesion to the mitochondrial genome. As there is no direct evidence for DOX causing mutations to either genome (Szikriszt et al., 2016) , the alterations in mitochondrial function and capacity observed may relate to modifications in gene expression through epigenetics. Previous studies of idiopathic CM identified deleterious changes in gene expression facilitated by modifications in DNA methylation status, one of the most common epigenetic mechanisms for gene expression control (Garcia et al., 2011; O'Donnell and Nabel, 2011) . Additionally, the discovery of DNA methyltransferase 1 translocation into the mitochondria provides evidence that mtDNA methylation is possible (Shock et al., 2011) . As the mitochondrion contains >1000 proteins (Calvo et al., 2016) , but only 13 of these are encoded by the mitochondrial genome itself, it is critical that any investigation of altered genome regulation includes both the nuclear and mitochondrial genomes. Therefore, we hypothesized that chronic DOX therapy is associated with epigenetic alterations to one or both genomes through modifications of DNA methylation status, particularly in genes important for mitochondrial function and capacity. Furthermore, we hypothesize that the cumulative and persistent mitochondrial toxicity (and thus, CM/CHF risk) induced by DOX therapy may, at least in part, be related to these alterations.
METHODS AND MATERIALS
Animal model. Male, Sprague Dawley rats were purchased from (Charles Rivers, Wilmington, MA) and communally housed in an AAALAC accredited facility at the University of Minnesota Medical School Duluth campus with climate control and free access to food and water. Rats initially weighing 76-100 g were randomly assigned to a treatment group and received subcutaneous injections of DOX-HCl (APP Pharmaceuticals, Los Angeles, CA) dissolved in saline (SAL) once a week for 6 weeks, given in doses of 2 mg/kg (s.c.) or an equivalent volume of SAL, 1 ml/kg (Berthiaume and Wallace, 2007b) . Dorsal injection sites were rotated to minimize local tissue irritation. Following the last dose of DOX, animals were allowed 5 weeks of drug-free holiday (6 þ 5); no mortality was noted in any of the treatment groups. At the conclusion of the 6 þ 5 treatment, body weights (BWs) were recorded and animals were anesthetized with CO 2 and subsequently killed by thoracotomy. Hearts were quickly excised, weighed, and immediately frozen in liquid nitrogen. Heart tissue was stored at À80 C until processed further.
DTNB assay. Oxidative stress was quantified in terms of the depletion of nonprotein sulfyhydryl groups using Ellman's Reagent (5,5'-dithio-bis-(2-nitrobenzoic acid); DTNB). Briefly, CryoMilled cardiac tissue was resuspended in 1Â phosphate buffered SAL then acidified using 6% trichloroacetic acid. The precipitate was pelleted and removed, 50 ll of supernatant from each sample was transferred to a 96-well microplate and then neutralized with 200 ll 0.3 M Na 2 HPO 4 (pH 8.2). In total 5 ll of a mixture containing 0.04% DTNB and 10% Na-citrate was then added to each well, mixed, and absorbance measured at 412 nm. Glutathione was used to generate a standard curve for calibration purposes.
Global methylation quantification. Genomic DNA (gDNA) from the frozen, CryoMilled cardiac tissues was isolated using the DNeasy Extraction kit (QIAGEN, Hilden, Germany.) Global levels of 5-methylcytosine (5-mC) were quantified using the MethylFlash Methylated DNA (meDNA) 5-mC Colorimetric Kit (EpiGentek, Farmingdale, NY.)
Methylome sequencing and analysis. gDNA was extracted from tissues using the DNeasy Extraction kit (QIAGEN, Hilden, Germany), and samples quantitated and purity assessed by Nanodrop spectrophotometry and Picogreen assay. Reduced Representation Bisulfite Sequencing (RRBS) libraries were prepared and then size selected in a target range of 160-340 bp using Caliper XT 750 lab chip; amplified pools were quality checked on Agilent DNA High Sensitivity chip. Bisulfite conversion was performed using the Methylcode kit (Invitrogen, Carlsbad, CA) and a post conversion PCR and clean-up was performed. Final size selected libraries were sequenced on a HISeq 2000 100 bp paired end run using TruSeq SBS v3 chemistry with a target depth of 20 million pass filter reads. Primary analysis and demultiplexing was performed using Illumina CASAVA Pipeline version 1.8. Bisulfite sequenced reads were aligned to the rat reference genome (downloaded from the UCSC server, build 5) using Bismark (Krueger and Andrews, 2011) and Bowtie (Langmead et al., 2009) . Out of a total of 4 353 863 methylated sites, analysis was restricted to the 407 321 sites which were present in at least 5 of the 10 control and 5 of the 10 experimental samples. Using a false discovery rate (FDR) of 0.05 with the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) , 2985 sites were considered for over-representation in clustering near genes. A simulation with sites chosen uniformly across the genome was used to screen for significance of clusters of differentially methylated sites near genes, which generated the short list of genes considered for further PCR verification.
Reverse transcriptase PCR and Quantitative PCR. Total RNA was isolated using the QIAGEN RNeasy kit (QIAGEN, Hilden, Germany.) Reverse transcriptase PCR (RT-PCR) was performed according to manufacturer's instructions (Omniscript RT kit, QIAGEN, Hilden, Germany) using 1.0 lg of total RNA to generate cDNA. RT-PCR was multiplexed, using the lower primer for both 18 S and the gene of interest to allow for normalization of transcript copy number. Primers were designed for each target of interest using sequence information from the GenBank database (Benson et al., 2013) with Primer-BLAST, and are listed in Supplementary Table 1. Relative expression of selected genes was evaluated using quantitative PCR (qPCR) by calculating the ratio of the specific gene to 18 S rRNA copy number, which served as the housekeeping gene. Optimization of primer sets was accomplished using HotStart PCR mix (QIAGEN, Hilden, Germany) to amplify desired products. Products were verified by melting curve analysis and gel electrophoresis. After optimization of reaction kinetics, amplified products were purified using the QIAquick PCR cleanup kit (QIAGEN, Hilden, Germany) and used to generate standard curves for each target sequence based on "copy number". QPCR reactions were performed, as described by Berthaiume and Wallace (2007b) , using the FastStart Kit (Roche Diagnostics) with minor modifications.
Western blot. Frozen, CryoMill homogenized cardiac tissue was resuspended in RIPA buffer, and whole cell lysate was generated by sonication on ice. Total protein abundance in each sample was determined using the BCA Protein Assay (Pierce, Waltham, MA), after which sample volumes were adjusted to normalize the total protein concentration. Each sample was chemically reduced using b-mercaptoethanol in the SDS-loading buffer. Total reduced Klhl29, Nmnat2, and b-actin immunoreactive proteins were determined by quantitative western blot analysis using rabbit polyclonal anti-Klhl29 (Abcam Cambridge, UK), antiNmnat2 (Abcam, Cambridge, UK), and anti-b-actin (Abcam, Cambridge, UK). The SuperSignal West Pico Chemiluminescent Substrate kit (Pierce, Waltham, MA) was used to detect bound antibody by enhanced chemiluminescence. The western blot data were imaged using a FluorChem HD2 MultiImager (Alpha Innotech, San Leandro, CA) and densitometry analyzed with the ImageJ software (U.S. NIH, Bethesda, MD).
Data analysis for functional characterization studies. Treatment groups were analyzed for statistically significant differences from control by 1-way ANOVA followed by the Tukey-Kramer HSD post hoc test for multiple comparisons among treatment groups. Differences with a p-value .05 were considered statistically significant. All analyses were performed using JMP Pro 10.0.0 software (SAS Institute Inc, Cary, NC.).
RESULTS

DOX Causes Persistent Alterations to Animal Growth and Tissue Oxidative Stress
Five weeks after the last of 6 weekly injections of DOX (6 þ 5), the rats appeared to be in generally good health with no mortality in either treatment group. Table 1 provides data on heart (HW) and BWs for both the DOX and SAL groups. DOX treated animals weighed significantly less (approximately 12%) than the SAL controls and also exhibited decreased cardiac masses. Additionally, the HW to BW ratios increased in the DOX treatment group (Table 1) . This alteration in HW/BW ratio may demonstrate the development of cardiomegaly from DOX therapy; however, the change in ratio is likely influenced as much by the loss of BW as it is by changes in HW.
Previous work in this laboratory identified and described the irreversible nature of DOX-induced oxidative mitochondrial toxicity in male Sprague Dawley rats using the same treatment protocol (Zhou et al., 2001a) . Consistent with those findings, 6 weekly injections of DOX, followed by 5 weeks of recovery, caused decreased levels of free sulfhydryl groups, as measured using DTNB (Figure 1 ) This indicates that DOX causes a persistent increase in cardiac tissue oxidative stress and that the current animal model is reliable.
Chronic DOX Exposure Alters the Methylation Landscape of the Genome
We hypothesize that the persistence associated with DOX toxicity is linked to altered regulation of gene expression through DNA methylation changes. Using frozen cardiac tissue, gDNA was isolated and used to quantify the global levels of 5-methylcytosine (5-mC) in each of the ten SAL and DOX samples. We observed a 24% decrease (p < .002) in 5-mC DNA of the treated cardiac samples (DOX) as compared with the control (SAL; Figure 2 ), warranting further investigation to identify the specific genes and nucleotide residues containing altered methylation status.
To identify and quantify the extent and specific nucleotide location of DOX-induced alterations to meDNA status in vivo, RRBS was coupled with Next-Gen Sequencing. Analysis of the sequencing data identified 50 genes and 153 distinct residues (Table 2) that demonstrated statistically significant differences in methylation status between the SAL and DOX groups. Both nuclear and mitochondrial genomes were mapped, and all 50 genes identified are encoded in the nuclear genome; there was no indication of altered methylation to the mitochondrial genome. Additionally, all of the 153 differentially methylated sites are located in the intronic regions of the genes and none in the promoter regions. Patterning of methylation changes was not seen within single genes; most exhibited both the addition and removal of methyl groups across the multiple residues affected in the gene. Furthermore, computational analyses of the methylated genes on potential signaling pathway interactions was pursued using the online tool DAVID (https://david.ncifcrf.gov/ home.jsp), but there were no statistically significant clusters for the methylated genes identified in Table 2 . DAVID uses a variety of annotations and databases, making it quite comprehensive; therefore, it is unlikely that any clear pathway would come out of other analyses.
DOX-Induced Methylation Changes Are Associated With Altered Transcription and Translation
Functional effects of DNA methylation changes were assessed by quantifying both mRNA and protein expression in a selected subset of the identified genes. Genes selected for further analysis had a minimum of 4 residues that were differentially methylated and encoded a protein that was clearly linked to cardiac function or had multiple variants that showed up on the list of significantly altered genes. A total of 7 genes were identified using these criteria, but we were unable to create working RT-qPCR primers for 2 (Pcdhga3, Cacng2). Of the 5 remaining selected targets (Rbm20, Cacna1c, Nmnat2, Scn5a, and Klhl29), DOX exposure significantly altered mRNA expression of 3 (Figure 3 ) Subsequent protein expression analysis via western blotting of the 3 genes with altered mRNA expression (Rbm20, Nmnat2, Klhl29) demonstrated a loss of both Klhl29 protein (À0.54 fold, p ¼ .002) and Nmnat2 protein (À0.61 fold, p ¼ .031) (Figure 4 ) (No protein data for Rbm20 was obtained because there is not a reliable commercial antibody available for this protein in rats. Additionally, because there was not a significant change in mRNA expression for Cacna1c and Scn5a, protein expression was not assessed.) Of note, the loss of Klhl29 and Nmnat2 mRNA expressions are associated with the decreases in the translated protein quantities observed. A corroborative analysis was performed to test the quantitative association of DNA methylation changes and corresponding changes to the gene expressions observed (Table 3) Two of the five genes, Rbm20 and Klhl29, contained methylation changes that were significantly associated with alterations to the mRNA expression. Loss of a methyl group after DOX treatment from either of 2 residues in Rbm20 correlated to an increase in expression of that gene, whereas the addition of a methyl group after DOX treatment on either of 2 residues in Klhl29 correlated to a decrease in gene expression. Additionally, the loss of Klhl29 gene expression was associated with a decrease in protein, indicating that the addition of a methyl group at these specific residues correlates with a functional decline of the Klhl29 gene.
DISCUSSION
In this study, using an epigenotype-to-phenotype approach, we observe that chronic DOX exposure alters the methylation landscape of gDNA. We show for the first time that chronic DOX exposure is accompanied by decreased global DNA methylation in cardiac tissue. Moreover, we identified that the most substantially transformed regions of the methylome correspond to several genes that are relevant for cardiac function and disease. We selected 5 of these genes (Rbm20, Cacna1c, Scn5a, Klhl29, and Nmnat2) to further investigate whether the altered methylation status had an impact on the expression and function of the gene.
Although we identified 153 significantly altered methylation residues (representing 50 distinct genes), we recognize that our utilization of RRBS to resequence the DOX-methylome has some limitations that are worth noting. The major limitation of RRBS, particularly as compared with whole genome bisulfite sequencing, is that it sequences only CpG-rich regions of the genome (CpG islands, shores, and shelves.) This approach often misses the intergenic and distal regulatory regions (where many enhancers are located), as well as CpG residues outside proximity to the restriction enzymes' recognition sites (Chinnery et al., 2012) . As such, the 153 differentially methylated residues identified in this study do not represent an exhaustive list of all methylation changes that may occur in response to DOX therapy, but rather a first-pass look at the impact of this drug on CpG enriched regions of the genome. Restriction digest enzymes used in RRBS are less likely to capture methylation changes to single or small clusters of CpG residues in the mitochondrial genome as compared with the nuclear. This is because the mitochondrial genome contains far fewer CpG dinucleotides than would be expected, and these CpG residues appear to be clustered around the origin of light-strand synthesis (O L ) more than any other region of the mitochondrial genome (Yong et al., 2016) . Thus, the fact that our study found no significantly altered methylation status within the mitochondrial genome should be interpreted with knowledge that much of the mitochondrial genome was likely not captured by the RRBS method. Our observation of an altered methylome likely underestimates the extent of change that occurs after DOX exposure.
The most significantly altered methylation state was found in the gene Rbm20 (a spliceosome protein), where 7 distinct nucleotide residues were altered compared with the controls. Rbm20 is a critical regulator of cardiac function through its action on titin and tropomyosin (biomechanics), Cacna1c and CamkIId (ion homeostasis and electrical activity), and Spen (signal transduction) (Guo et al., 2012; Wyles et al., 2016) . Loss-offunction mutations for Rbm20 have been identified in 1.9%-3% Protein phosphatase 1, regulatory subunit 7 3 Tanc1
Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 3
Number indicates how many sites in the gene had a different methylation status from the SAL control group; this does not distinguish whether that difference was the addition or removal of a methyl group. Genes denoted with * and boldface indicate those further studied for functional characterization of the methylation status change.
of individuals with idiopathic dilated cardiomyopathy (Brauch et al., 2009; Gerull et al., 2002; Guo et al., 2012; Li et al., 2010) . The role of Rbm20 in splicing of titin is of particular relevance, as titin is a sarcomeric protein that determines the passive elasticity of striated muscle and has recently been associated with human cardiac disease (Gerull et al., 2002; Guo et al., 2012; Maatz et al., 2014; Wyles et al., 2016) . Furthermore, in vitro studies of missense Rbm20 mutations have demonstrated development of CMs with defective Ca 2þ handling machinery, prolonged Ca 2þ levels, and higher Ca 2þ amplitude spike as the result of differential Cacna1c isoform expression from altered Rbm20-dependent splicing (Wyles et al., 2016) . Heritable forms of CM have been linked to loss-of-function mutations in Rbm20, but recent geneexpression profiling of African American (AA) versus European American (EA) populations identified a strong association of increased Rbm20 gene expression (1.64-fold) in the AA population with an increased risk of developing heart failure (Halder et al., 2016) . Of considerable interest, our studies identified Rbm20 as the most differentially methylated gene after chronic exposure to DOX in rats, and the cumulative changes in methylation marks resulted in increased expression of Rbm20. Moreover, methylation status at 2 of the 7 residues identified were statistically significant for correlation with changes in Rbm20 expression, suggesting that loss of the methyl group from one or both of these residues may be responsible for the increased gene expression observed in the DOX group. Considering the role that Rbm20 plays in regulating biomechanical and electrical properties of cardiac function, altered expression via epigenetic modifications may have a very real impact on development of CM. More specifically, we observed an increase in expression of Cacna1c after DOX treatment, although it was not statistically significant. It is worth considering the 0.00E+00 possibility that rather than altering total expression of this gene, the increase in Rbm20 may be impacting the splicing and formation of variant Cacna1c, thus contributing to development of CM through this mechanism as well.
Of the 5 genes we selected to study further, 2 are involved in cardiac ion channel function: Cacna1c encodes a subunit of the L-type voltage-dependent calcium channel, and Scn5a encodes a subunit of the voltage-gated type V sodium channel. We observed a DOX-induced decrease in Scn5a gene expression that was not statistically significant, but repetitive targeting and cumulative methylation of this gene throughout an individual's life may lead to later development of cardiotoxicity and heart failure following DOX therapy. The cardiac sodium channel facilitates the rapid depolarization phase of the cardiac action potential, forming a critical element of cardiac excitability and conduction (Bezzina and Remme, 2008) . Loss of function mutations in Scn5a have been linked to a broad spectrum of primary arrhythmia disorders (eg, long QT syndrome, sick sinus syndrome, conduction disease, atrial fibrillation), which until recently have been considered to occur in the absence of structural heart disease (Darbar et al., 2008; Wilde and Bezzina, 2005) . However, new evidence is emerging that suggests sodium channelopathy may also be associated with the development of dilation, hypertrophy, and cardiac fibrosis, which would in turn predispose to the development of arrhythmias (Bezzina et al., 2003; Coronel et al., 2005; Frustaci et al., 2005; Ge et al., 2008; McNair et al., 2004; Olson et al., 2005) . Although the mechanism by which these channelopathies lead to myocardial structural changes is as of yet unknown, this raises the interesting possibility that structural alterations observed in long-standing sodium channelopathies may be the direct consequence of channel dysfunction, rather than the long-standing arrhythmia (Bezzina and Remme, 2008) . Considering the mild loss of Scn5a expression that we observed after chronic DOX treatment, it becomes possible that this initial altered methylation to the sodium channel gene may be perpetuated over an extended period of time, perhaps accumulating further injury and leading to an eventual sodium channelopathy that results in structural changes to the myocardium and causes CM or CHF.
Among the genes that we identified as significantly differentially methylated post-DOX treatment is Klhl29 (kelch-like family member 29), a conserved gene with a poorly annotated function. We found chronic DOX treatment was associated with decreased Klhl29 gene and protein expression, and that the methylation statuses for 2 of the identified residues were inversely correlated with Klhl29 expression. Specifically, the addition of a methyl group at either 1 of these 2 residues correlated with increased gene expression. Although the function of Klhl29 is generally unknown, several genome wide association studies have recently linked polymorphisms within Klhl29 to increased risk of cardiovascular disease, obesity, and chronic kidney disease (Chan et al., 2014; Gottesman et al., 2012; Halder et al., 2016) . Additionally, genetic predisposition to cardiovascular disease (such as Klhl29 polymorphism or perhaps altered methylation status) has been suggested to potentiate DOX cardiotoxicity events (Fettig et al., 2006) . The changes in methylation status, as well as gene and protein expression that we have identified as a result of DOX exposure indicate that Klhl29 might be targeted for further investigation to determine the gene function and role in cardiovascular disease, as it may pertain to the cumulative insult from DOX that leads to cardiotoxicity.
The last of the 5 genes we selected to functionally characterize was Nmnat2 (nicotinamide mononucleotide adenylyltransferase), a central enzyme that catalyzes the final step of nicotinamide adenine dinucleotide (NAD) biosynthesis. Nmnat2, unlike the other 2 isoforms (Nmnat1 and Nmnat3), is closely involved in energy metabolism and primarily expressed in tissues with high energy consumption needs (ie, heart, brain, and skeletal muscle) (Berger et al., 2005) . Maintaining adequate levels of intracellular NAD is essential for many critical processes beyond energy metabolism, such as intracellular Ca 2þ regulation and regulation of sirtuins (SIRTs) (Canto et al., 2009; Pillai et al., 2005; Zima et al., 2004) . SIRTs are a family of NAD-dependent deacetylases, the mRNA of which can be significantly increased by NAD directly (Hayashida et al., 2010) . SIRTs have also been shown to protect cardiomyocytes from oxidative stress-mediated cell death and slow some age-associated cardiac degenerative changes (Hsu et al., 2008; Zheng and Lu, 2011) . Thus, it is not surprising that overexpression of Nmnat2 has been demonstrated to be protective against cardiac hypertrophy (through its ability to increase NAD content and subsequently SIRT activity) (Cai et al., 2012) , and that Nmnat2 protein expression and enzyme activity are down-regulated in cases of cardiac hypertrophy (Pillai et al., 2010) . In this study, we identified Nmnat2 as being differentially methylated after DOX exposure, and reported a decrease in both the gene and protein expression. In the context of DOX-induced cardiotoxicity, which typically manifests as dilated cardiomyopathy and CHF and is thought to be due in part to increased levels of oxidative stress, Nmnat2 expression and function may play an important protective role, much like it does in hypertrophic cardiomyopathy. Our laboratory is the first to sequence the DOX methylome in rats and to demonstrate the change in DNA methylation with the DOX-induced cardiotoxicity observed. Unlike previous reports for human breast cancer tissue following clinical DOX therapy (Dejeux et al., 2010; Klajic et al., 2014) , we found no altered methylation status for promoter regions within the cardiac gDNA. Zhang et al. (2011) suggest that the differential regulation of DNA methyltransferase and p21 by DOX plays a critical role in governing in determining the fate of colorectal cancer cells in culture.
Functional characterization of Rbm20, Klhl29, and Nmnat2 suggests possible associations with heart failure and revealed a correlation between the altered methylation status and the mRNA and protein expression levels of these genes. These findings have the potential to contribute significantly to increased understanding of DOX cardiotoxicity and the mechanism(s) by which this toxicity persists long after discontinuation of therapy. Although involvement of these genes in cardiovascular diseases has previously been described, we report novel DNA methylation changes that may contribute to their involvement in DOX-induced CM and CHF. The question remains, however, whether these changes in methylation status are the result of the general toxicity of DOX or if they account for the toxicity observed (and if so, are they representative specifically of DOXinduced cardiac toxicity, or are these alterations more broadly characteristic of most forms of CM and CHF.) This insight could reveal potential targets for further investigation, which may ultimately improve the overall efficacy of this clinically important drug, provide valuable insight into other forms of CM and CHF, and yield novel therapeutic targets aimed at the universal prevention of cardiac failure.
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